AstraZeneca ilandila kulimbikitsidwa kwamankhwala a oncology

AstraZeneca idalimbikitsidwa kawiri pazamankhwala ake a oncology Lachiwiri, pambuyo poti olamulira aku US ndi ku Europe avomereza kuwongolera kwamankhwala ake, gawo loyamba lopambana kuvomerezedwa kwa mankhwalawa.

The Anglo-Swedish drugmaker, ndi MedImmune, bungwe lake lofufuza ndi chitukuko cha biologics padziko lonse lapansi, adalengeza kuti US Food and Drug Administration (FDA) yavomereza pempho la chilolezo cha moxetumomab pasudotox, mankhwala atsopano omwe angathe kuchiza odwala akuluakulu omwe ali ndi tsitsi. khansa ya m'magazi (HCL) omwe adalandirapo mankhwala osachepera awiri am'mbuyomu.

A FDA apereka udindo wa "kuwunika patsogolo" kwa mankhwalawa, omwe amaperekedwa kwa mankhwala omwe, ngati avomerezedwa, angapereke kusintha kwakukulu pamankhwala, kuzindikira, kapena kupewa zovuta. Chisankho chikuyembekezeka mu gawo lachitatu la chaka chino.

Payokha, European Medicines Agency idavomereza kugonjera kwa Lynparza, mankhwala omwe AstraZeneca tsopano ali nawo mumgwirizano wa 50:50 ndi Merck, kampani yaku US mankhwala, kuchiza khansa ya m'mawere yomwe imafalikira kwina kulikonse m'thupi kwa odwala omwe ali ndi vuto linalake. kusintha kwa chibadwa.

Ngati atavomerezedwa, mankhwalawa angakhale woyamba PARP inhibitor pochiza khansa ya m'mawere ku Ulaya. PARP ndi puloteni yomwe imapezeka m'maselo a anthu yomwe imathandiza kuti maselowo adzikonze okha akawonongeka. Poyimitsa njira yokonzanso m'maselo a khansa, PARP inhibitors amathandiza kuti selo life.

Lynparza mu Januwale adakhala woyamba PARP inhibitor kuvomerezedwa kulikonse padziko lapansi chifukwa cha khansa ya m'mawere, pomwe idapambana kutsogola kuchokera kwa oyang'anira aku US.

M'mayesero aposachedwa, Lynparza adatalikitsa kupulumuka kopanda kupita patsogolo poyerekeza ndi chemotherapy ndikuchepetsa chiwopsezo chakukula kwa matenda kapena kufa ndi 42 peresenti.

Mu 2017 gawo limodzi mwa magawo asanu mwazogulitsa za Astra zidachokera ku oncology ndipo kampaniyo ikuyembekeza kuti gawoli likwera. Magawo mgulu adatseka 0.6 peresenti pa £49.26.

Mwanjira ina, Compugen, kampani yaku Israeli yopangira mankhwala, idati idachita mgwirizano wapadera ndi MedImmune womwe ungathandize kupanga mankhwala oletsa antibody kuchiza khansa.

MedImmune ili ndi ufulu wopanga zinthu zingapo pansi pa chilolezo "ndipo idzakhala ndi udindo wofufuza, chitukuko ndi ntchito zamalonda pansi pa mgwirizanowu", adatero Compugen.

Kampani ya Israeli ilandila ndalama zokwana $ 10m ndipo ikuyenera kulandira mpaka $200m pakutukuka, kuwongolera komanso kuchitapo kanthu pazamalonda pazogulitsa zoyamba, komanso zolipira pazogulitsa zamtsogolo.

Anat Cohen-Dayag, wamkulu wamkulu wa Compugen, adati mgwirizanowu "umatilola kupanga ndalama zopititsa patsogolo zasayansi pamapulogalamu athu, pomwe tikupitiliza kupititsa patsogolo mapulogalamu athu otsogolera mayeso azachipatala".